Antiaging compounds: (-)Deprenyl (selegiline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain

CNS Drug Reviews

Volumn 7, Issue 3, 2001, Pages 317-345

  Knoll, J ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Antiaging drugs; BPAP; Deprenyl; Selegiline

Indexed keywords

1 (BENZOFURAN 2 YL) 2 PROPYLAMINOPENTANE; 1 (INDOL 3 YL) 2 PROPYLAMINOPENTANE; AMPHETAMINE; BENZOFURAN DERIVATIVE; CATECHOLAMINE; METHAMPHETAMINE; PHENETHYLAMINE; SELEGILINE; SEROTONIN; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

AGING; ANIMAL EXPERIMENT; BRAIN FUNCTION; CATECHOLAMINE RELEASE; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; LIFESPAN; MALE; NEUROLOGIC DISEASE; NONHUMAN; QUALITY OF LIFE; RAT; REVIEW; SEROTONIN RELEASE;

EID: 0035679477     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2001.tb00202.x     Document Type: Review

References (86)

1. CBF and cognitive evaluation of Alzheimer-type patients before and after MAO-B treatment: A pilot study
2. Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMP)
3. L-Deprenyl treatment in aged mice slightly increases lifespans and greatly reduces fecundity by aged males
4. Der L-Dioxyphenyl-alanin-Effekt beim Parkinson Syndrom des Menschen
5. Parkinson Disease
6. Implications of combined treatment with "Madopar" and L-Deprenil in Parkinson's disease
7. L-Deprenyl plus L-phenylalanine in the treatment of depression
8. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A long-term study
9. L-Deprenyl in the treatment of mild dementia of the Alzheimer type: Results of a 15-month trial
10. Selegiline versus L-acetylcamitine in the treatment of Alzheimer-type dementia
11. (-)Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathion peroxidase in the striatum of young male rats
12. (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: The sex- and age-related differences in the optimal dose in the rat
13. Pargyline and (-)deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) in monkeys
14. Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the "cheese effect."
15. Selegiline versus oxiracetam in patients with Alzheimer-type dementia
16. Alzheimer-type dementia and verbal memory performances: Influence of selegiline therapy
17. L-deprenyl therapy improves verbal memory in amnesic Alzheimer patients
18. Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B
19. Long term administration of (-)deprenyl increases mortality in male Wistar rats
20. The use of selegiline in Alzheimer's patients with behavior problems
21. Evidence of deprenyl-insensitive apoptosis of nigral dopamine neurons during development
22. Inhibition by (-)-deprenyl of dopamine uptake in rat striatum: A possible correlation between dopamine uptake and acetylcholine release inhibition
23. Chronic treatment of aged mice with L-deprenyl produced marked MAO-B inhibition but no beneficial effects on survival, motor performance, or nigral lipofuscin accumulation
24. Chronic treatment of (-)deprenyl prolongs the lifespan of male Fischer 344 rats. Further evidence
25. Experimental studies on the higher nervous activity of animals. VI. Further studies on active reflexes
26. The Theory of Active Reflexes
27. Analysis of the pharmacological effects of selective monoamine oxidase inhibitors
28. The possible mechanism of action of (-)deprenyl in Parkinson's disease
29. Selective inhibition of B type monoamine oxidase in the brain: A drug strategy to improve the quality of life in senescence
30. Deprenyl (selegiline). The history of its development and pharmacological action
31. The striatal dopamine dependency of lifespan in male rats. Longevity study with (-)deprenyl
32. The pharmacology of selegiline/(-)deprenyl
33. Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity
34. Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases
35. Memories of my 45 years in research
36. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes
37. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain
38. Some puzzling effects of monoamine oxidase inhibitors
39. Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity. Rationale for prophylactic (-)deprenyl (selegiline) medication
40. Phenylisopropylmethyl-propinylamine (E-250), a new psychic energizer
41. Phenylisopropylmethylpropinylamine (E-250), a monoamine oxidase inhibitor antagonizing the effects of tyramine
42. Long-lasting, true aphrodisiac effect of (-)deprenyl in sexually sluggish old male rats
43. Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl
44. The pharmacology of 1-phenyl-2-propylaminopentane (PPAP), a deprenyl-derived new spectrum psychostimulant
45. (-)Deprenyl and (-)parafluorodeprenyl- treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelanin
46. Sexually low performing male rats die earlier than their high performing peers and (-)deprenyl treatment eliminates this difference
47. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons
48. Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain
49. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain
50. Sexual hormones terminate in the rat the significantly enhanced catecholaminergic/serotoninergic tone in the brain characteristic to the post-weaning period
51. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group
52. Selegiline hydrochloride and cognition
53. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
54. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease
55. A selective monoamine oxidase-B inhibitor in endogenous depression
56. Sexual activity in the aging male
57. Brief information on an early phase-II study with (-)deprenyl in demented patients
58. Maintenance on L-(-)deprenyl prolongs life in aged male rats
59. Selegiline in the treatment of mild to moderate Alzheimer-type dementia
60. Selegiline as initial treatment in de novo parkinsonian patients
61. Effect of (-)deprenyl on the progression disability in early Parkinson's disease
62. Effect to tocopherol and (-)deprenyl on the progression of disability in early Parkinson's disease
63. Impact of deprenyl and tocopherol treatment of Parkinson's disease in DATATOP patients requiring levodopa
64. Amphetamine, p-hydroxyamphetamine and β-phenylethylamine in mouse brain and urine after (-)- and (+)-deprenyl administration
65. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia
66. Absence of "cheese effect" during deprenyl therapy: Some recent studies
67. Deprenyl is metabolized to methamphetamine and amphetamine in man
68. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease
69. Treatment with L-deprenyl prolongs life in elderly dogs
70. Rationale and design of a multicenter study of selegiline and α-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes
71. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
72. A pilot study of low-dose L-deprenyl in Alzheimer's disease
73. Chronic treatment of Syrian hamsters with low-dose selegiline increases lifespan in females but not males
74. Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells
75. L-(-)deprenyl in Alzheimer's disease
76. Apoptotic mechanisms in neurodegeneration: Possible relevance to glaucoma
77. The effect of (-)deprenyl (selegiline) on the natural history of Parkinson's disease
78. The effect of L-E-250 (-L- phenyl-isopropylmethyl-propinyl-amine HC1) in depression
79. Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decrease the incidence of mammary and pituitary tumors in old acyclic rats
80. Antitumor effct of L-deprenyl in rats with carcinogen-induced mammary tumors
81. Vorläufiger bericht fiber die wirkung des präparates E-250 (phenyl- isopropyl-methyl-propinylamine-chlorhydrat)
82. Clinical trial of a new type of promptly acting psychoenergetic agent (phenyl-isopropylmethyl-propinylamine HCl, E-250)
83. Protective effect of deprenyl against 1-methyl-4-phenylpyridinium neurotoxicity in rat striatum
84. + in vivo
85. Preclinical evaluation of 1-deprenyl: Lack of amphetamine-like abuse potential
86. Extension of lifespan in mice treated with Dinh lang (Policias fruticosum L) and (-)deprenyl